The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | Alive

Total Raised


Last Raised

$90K | 5 mos ago

About Novo

Novo is a "slow fashion" womenswear producer that provides made-to-last garments.

Novo Headquarter Location

Whitfield House, Whitfield Court , St Johns Road, Meadowfield Ind Estate

Durham, England, DH7 8XL,

United Kingdom

0800 6446686

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Novo News

Lilly wins FDA approval of new kind of diabetes drug

May 13, 2022

Mounjaro helped improve blood sugar control in testing and has been shown to have powerful weight loss effects as well. Published May 13, 2022 The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients' blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies. The company recorded $9 billion in diabetes drugs sales last year. Mounjaro works by stimulating two hormones, called GLP-1 and GIP, that control insulin production. In clinical testing, the drug outperformed several other diabetes medicines, including one made by rival drugmaker Novo Nordisk that only acts on one hormone. Mounjaro was more effective in controlling blood sugar than two types on insulin as well. "Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type 2 diabetes," said Patrick Archdeacon, associate director of the diabetes division in FDA’s Center for Drug Evaluation and Research, in a statement . Like Trulicity and other drugs in its class, Mounjaro’s most common side effects are nausea, vomiting, diarrhea and other gastrointestinal problems. The company did not announce Mounjaro’s price and did not respond to BioPharma Dive's questions by publication. The drug's approval will heighten competition between Lilly and Novo, which have battled for market share in the U.S. for years. Novo, for instance, has recently had success by launching a similar, once-weekly shot to Lilly's top-selling drug Trulicity, as well as a daily pill that works the same way. Novo is testing a dual-acting competitor to tirzepatide, but it's only in Phase 2 testing, well behind Lilly's drug. Both companies are also trying to develop a once-weekly insulin shot, with similar programs in Phase 3 development. The next frontier for both companies is in obesity, where they are working to prove their drugs' worth as weight loss treatments. Novo has already won approval for a drug called Wegovy, while Lilly reported promising data for Mounjaro last month. Recommended Reading

Novo Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Novo Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.